摘要
目的观察男性良性前列腺增生伴下尿路症状患者在接受坦索罗辛治疗后仍然存在的膀胱过度活动症加用索利那新的治疗作用。方法选取大于50岁的的良性前列腺增生伴下尿路症状患者,均先接受4周的坦索罗辛0.2mg治疗,再次评估时仍然有OAB症状者纳入本组观察,予索利那新5mg+坦索罗辛0.2mg治疗4周。观察项目包括国际前列腺症状评分(IPSS)、生活质量指数(QOL)、膀胱活动症症状评分(OABSS)、最大尿流率(Qmax)和残余尿量(PVR)等。结果 112例患者接受坦索罗辛治疗,治疗4周后62例(55.4%)符合纳入标准,58例完成研究,平均年龄67.2岁。IPSS评分(14.4到10.8)、QOL指数(4.4到3.2)及OABSS(6.1到3.9)显著提高,虽然IPSS储尿期症状评分显著改善(10.8到7.4),IPSS排尿期症状无显著改变,治疗前后Qmax和PVR无明显变化。结论男性良性前列腺增生伴下尿路症状患者在接受坦索罗辛治疗后仍然存在的膀胱过度活动症中加用索利那新安全有效。
Objective To observe the therapeutic effect of solifenacin on male patients who still have overative bladder after treatment with tamsulosin monotherapy for benign prostatic hyperplasia accompanied with lower urinary tract symptoms. Methods Clinically selected over 50-year-old male patients who had benign prostatic hyperplasia accompanied with lower urinary tract symptoms. Firstly,all of the patients received tamsulosin treatments（ 0. 2 mg） for 4 weeks,after evaluating,patients who still had OAB symptoms would be included in this observation group and then,treated the group with solifenacin（ 5mg） and tamsulosin（ 0. 2mg） for 4 weeks. The observation items included the International Prostate Symptom Score（ IPSS）,the quality of life index（ QOL）,the symptom score（ OABSS）,the maximum flow rate（ Qmax）,and residual urine volume（ PVR）,etc. Results Among 112 patients who received tamsulosin treatment for 4 weeks,62 patients（ 55. 4%） met the inclusion criteria and 58 patients completed the study,the average age was 67. 2 years old. IPSS score（ 14. 4 to 10. 8）,QOL index（ 4. 4 to 3. 2） and OABSS（ 6. 1to 3. 9） were significantly improved. Although the symptom score of IPSS during urinary storage period was significantly improved（ 10. 8 to 7. 4）,the symptoms of IPSS during micturition period were not significantly changed,the PVR and Qmax had no significant changes before and after treatment. Conclusion Solifenacin had a safe and effective result on male patients with benign prostatic hyperplasia accompanied with lower urinary tract symptoms who still had overative bladder after treatment of tamsulosin.
出处
《四川医学》
CAS
2016年第2期164-167,共4页
Sichuan Medical Journal
